

## **Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients**

### **COG Supportive Care Endorsed Guidelines**

Click [here](#) to see all the COG Supportive Care Endorsed Guidelines.

#### DISCLAIMER

**For Informational Purposes Only:** The information and contents offered in or in connection with the *Children's Oncology Group Supportive Care Endorsed Guidelines* (the "Guidelines") is provided only for informational purposes to children affected by cancer, their families and their health care providers. The Guidelines are not intended to substitute for medical advice, medical care, diagnosis or treatment obtained from doctors or other healthcare providers.

While the Children's Oncology Group tries to provide accurate and up-to-date information, the information in the Guidelines may be or may become out of date or incomplete. The information and guidelines may not conform to current standard of care, state-of-the art, or best practices for a particular disease, condition, or treatment. Some information in the Guidelines may be intended to be used by clinical researchers in special clinical settings or situations that may not apply to you, your child or your patient.

**Special Notice to cancer patients and their parents and legal guardians:** The Children's Oncology Group is a research organization and does not provide individualized medical care or treatment.

*The Guidelines are not intended to replace the independent clinical judgment, medical advice, screening, health counseling, or other intervention performed by your or your child's doctor or other healthcare provider. Please do not rely on this information exclusively and seek the care of a doctor or other medical professional if you have any questions regarding the Guidelines or a specific medical condition, disease, diagnosis or symptom.*

*Please contact "911" or your emergency services for any health emergency!*

**Special Notice to physicians and other healthcare providers:** This document is aimed specifically at members of the Children's Oncology Group or Member affiliates who have agreed to collaborate with the Children's Oncology Group in accordance with the relevant procedures and policies for study conduct and membership participation. Requirements and restrictions applicable to recipients of U.S. governmental funds or restrictions governing certain private donations may apply to the use and distribution of the Guidelines and the information contained herein.

The Guidelines are not intended to replace your independent clinical judgment, medical advice, or to exclude other legitimate criteria for screening, health counseling, or intervention for specific complications of childhood cancer treatment. The Guidelines provided are not intended as a sole source of guidance in the evaluation of childhood cancer patients. Nor are the Guidelines intended to exclude other reasonable alternative care. Specific patient care decisions are the prerogative of the patient, family and healthcare provider.

**Warranty or Liability Assumed by Children's Oncology Group and Related Parties:** While the Children's Oncology Group has tried to assure that the Guidelines are accurate and complete as of the date of publication, no warranty or representation, express or implied, is intended to be made in or with the Guidelines. No liability is assumed by the Children's Oncology Group or any affiliated party or member thereof for damage resulting from the use, review, or access of the Guidelines.

This document summarizes four clinical practice guidelines on the topic of chemotherapy-induced nausea and vomiting:

- I. The "[Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline](#)" developed by the Pediatric Oncology Group of Ontario (POGO) (endorsed by the COG Supportive Care Guideline Task Force in August 2019)
- II. The "[Antiemetics: ASCO Guideline Update](#)" developed by the American Society of Clinical Oncology (endorsed by the COG Supportive Care Guideline Task Force in December 2020)
- III. The POGO's "[Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline](#)" developed by POGO (endorsed by the COG Supportive Care Guideline Task Force in February 2023)
- IV. The "[Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update](#)" developed by POGO (endorsed by the COG Supportive Care Guideline Task Force in July 2021) and
- V. The "[Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update](#)" developed by POGO (endorsed by the COG Supportive Care Guideline Task Force in December 2023).

### **I. Classification of Chemotherapy Emetogenicity**

The "Classification of the Acute Emetogenicity of Chemotherapy in Pediatric Patients: A Clinical Practice Guideline" developed by the Pediatric Oncology Group of Ontario was endorsed by the COG Supportive Care Guideline Committee in August 2019.

The source guideline is published (Paw Cho Sing E, Robinson PD, Flank J et al. *Pediatr Blood Cancer*. 2019; 66: e27646.) and is available at <https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.27646>. It is an update of an earlier guideline that was published in 2011.

The purpose of this guideline is to provide evidence-based recommendations regarding the acute emetic potential of chemotherapy in pediatric oncology patients aged 1 month to 18 years. The recommendations of the endorsed guideline are presented below.

## Summary of Recommendations for the Classification of Chemotherapy Emetogenicity

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>1. Which chemotherapy regimens are highly emetogenic?</b>	
<p>Single-agent regimens:</p> <ul style="list-style-type: none"> <li>Asparaginase (<i>Erwinia</i>) IV <math>\geq 20,000</math> IU/m<sup>2</sup>/dose</li> <li>Busulfan IV <math>\geq 0.8</math>mg/kg/dose</li> <li>Busulfan PO <math>\geq 1</math>mg/kg/dose</li> <li>Carboplatin IV <math>\geq 175</math> mg/m<sup>2</sup>/dose</li> <li>Cisplatin IV <math>\geq 12</math> mg/m<sup>2</sup>/dose</li> <li>Cyclophosphamide IV <math>\geq 1,200</math> mg/m<sup>2</sup>/dose</li> <li>Cytarabine IV <math>\geq 3</math>g/m<sup>2</sup>/day</li> <li>Dactinomycin IV <math>\geq 1.35</math> mg/m<sup>2</sup>/dose</li> <li>Doxorubicin IV <math>\geq 30</math> mg/m<sup>2</sup>/dose</li> <li>Idarubicin PO <math>\geq 30</math> mg/m<sup>2</sup>/dose</li> <li>Melphalan IV</li> <li>Methotrexate IV <math>\geq 12</math> g/m<sup>2</sup>/dose</li> </ul>	<p>Strong recommendation Very low to high quality of evidence</p>
<p>Multiple-agent regimens:</p> <ul style="list-style-type: none"> <li>Cyclophosphamide <math>\geq 600</math> mg/m<sup>2</sup>/dose + dactinomycin <math>\geq 1</math> mg/m<sup>2</sup>/dose</li> <li>Cyclophosphamide <math>\geq 400</math> mg/m<sup>2</sup>/dose + doxorubicin <math>\geq 40</math> mg/m<sup>2</sup>/dose</li> <li>Cytarabine IV <math>\geq 90</math> mg/m<sup>2</sup>/dose + methotrexate IV <math>\geq 150</math> mg/m<sup>2</sup>/dose</li> <li>Cytarabine IV + teniposide IV</li> <li>Dacarbazine IV <math>\geq 250</math> mg/m<sup>2</sup>/dose + doxorubicin IV <math>\geq 60</math> mg/m<sup>2</sup>/dose</li> <li>Dactinomycin IV <math>\geq 900</math> <math>\mu</math>g/m<sup>2</sup>/dose + ifosfamide IV <math>\geq 3</math> g/m<sup>2</sup>/dose</li> <li>Etoposide IV <math>\geq 60</math> mg/m<sup>2</sup>/dose + ifosfamide IV <math>\geq 1.2</math> g/m<sup>2</sup>/dose</li> <li>Etoposide IV <math>\geq 250</math> mg/m<sup>2</sup>/dose + thiotepa IV <math>\geq 300</math> mg/m<sup>2</sup>/dose</li> </ul>	

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>2. Which single-agent and multiple-agent chemotherapy regimens are moderately emetogenic?</b>	
<p>Single-agent regimens:</p> <ul style="list-style-type: none"> <li>Cyclophosphamide IV 1000 mg/m<sup>2</sup>/dose</li> <li>Cytarabine IV 75 mg/m<sup>2</sup>/dose</li> <li>Dactinomycin IV 10 µg/kg/dose</li> <li>Doxorubicin IV 25 mg/m<sup>2</sup>/dose</li> <li>Gemtuzumab IV 3–9mg/m<sup>2</sup>/dose</li> <li>Imatinib PO &gt; 260 mg/m<sup>2</sup>/day</li> <li>Interferon alpha IV 15–30 million U/m<sup>2</sup>/day</li> <li>Ixabepilone IV 3–10 mg/m<sup>2</sup>/dose</li> <li>Methotrexate IV 5 g/m<sup>2</sup>/dose</li> <li>Methotrexate IT</li> <li>Topotecan PO 0.4–2.3 mg/m<sup>2</sup>/day</li> </ul> <p>Multiple-agent regimens:</p> <ul style="list-style-type: none"> <li>Cytarabine IV 100 mg/m<sup>2</sup>/dose + daunorubicin IV 45 mg/m<sup>2</sup>/dose + etoposide IV 100 mg/m<sup>2</sup>/dose + prednisolone PO + thioguanine PO 80mg/m<sup>2</sup>/dose</li> <li>Cytarabine 60 or 90 mg/m<sup>2</sup>/dose + methotrexate 120 mg/m<sup>2</sup>/dose</li> <li>Liposomal doxorubicin IV 20–50 mg/m<sup>2</sup>/dose + topotecan PO 0.6mg/m<sup>2</sup>/day</li> </ul>	<p>Strong recommendation Very low to high quality of evidence</p>

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>3. Which single-agent and multiple-agent chemotherapy regimens are of low emetogenicity?</b>	
<p>Single-agent regimens:</p> <ul style="list-style-type: none"> <li>Cyclophosphamide IV 500 mg/m<sup>2</sup>/dose</li> <li>Cyclophosphamide PO 2–3 mg/kg/dose</li> <li>Dasatinib PO 60–120 mg/m<sup>2</sup>/dose</li> <li>Erlotinib PO 35–150 mg/m<sup>2</sup>/day</li> <li>Everolimus PO 0.8–9mg/m<sup>2</sup>/day</li> <li>Gefitinib PO 150–500 mg/m<sup>2</sup>/day</li> <li>Imatinib PO 260 mg/m<sup>2</sup>/day</li> <li>Mafofosamide IT 1–6.5 mg/dose</li> <li>Melphalan PO 0.2 mg/kg/dose</li> <li>Mercaptopurine PO ≤ 4.2mg/kg/dose</li> <li>Methotrexate 38–83 mg/m<sup>2</sup>/dose IV</li> <li>Mitoxantrone IV ≤ 33 mg/m<sup>2</sup>/dose</li> <li>Procarbazine PO 50–100 mg/m<sup>2</sup>/day</li> <li>Ruxolitinib PO 15–21 mg/m<sup>2</sup>/dose</li> <li>Selumetinib PO 20–30 mg/m<sup>2</sup>/dose</li> <li>Sorafenib PO 150–325 mg/m<sup>2</sup>/dose</li> <li>Temozolomide PO 200 mg/m<sup>2</sup>/dose</li> </ul> <p>Multiple-agent regimens:</p> <ul style="list-style-type: none"> <li>Cytarabine IV 60 mg/m<sup>2</sup>/dose + methotrexate IV 90 mg/m<sup>2</sup>/dose</li> </ul>	<p>Strong recommendation Very low to moderate quality of evidence</p>
<b>4. Which single-agent and multiple-agent chemotherapy regimens are minimally emetogenic?</b>	
<p>Single-agent regimens:</p> <ul style="list-style-type: none"> <li>Asparaginase (<i>E. coli</i>) IM ≤ 6000 IU/m<sup>2</sup>/dose</li> <li>Asparaginase (<i>Erwinia</i>) IM ≤ 25 000 IU/m<sup>2</sup>/dose</li> <li>Chlorambucil ≤ 0.2mg/kg/day PO</li> <li>Doxorubicin IV 10 mg/m<sup>2</sup>/dose</li> <li>Liposomal doxorubicin IV ≤ 50 mg/m<sup>2</sup>/dose</li> <li>Mercaptopurine PO ≤ 4.2mg/kg/dose</li> <li>Methotrexate PO/SC ≤ 10 mg/m<sup>2</sup>/dose</li> <li>Pracinostat PO 25–45 mg/m<sup>2</sup>/dose</li> <li>Vincristine IV ≤ 1.5mg/m<sup>2</sup>/dose</li> </ul> <p>Multiple-agent regimens:</p> <ul style="list-style-type: none"> <li>Cisplatin ≤ 60 mg/m<sup>2</sup>/dose intra-arterially + doxorubicin ≤ 30 mg/m<sup>2</sup>/dose intra-arterially</li> <li>Cisplatin ≤ 60 mg/m<sup>2</sup>/dose intra-arterially + pirarubicin ≤ 30 mg/m<sup>2</sup>/dose intra-arterially</li> <li>Mercaptopurine PO ≤ 2.5mg/kg/dose + methotrexate PO ≤ 0.1mg/kg/day</li> </ul>	<p>Strong recommendation Very low to low quality of evidence</p>

\*See Appendix 1

## II. Prevention of Acute Chemotherapy-induced Nausea and Vomiting

The “Antiemetics: ASCO Update” developed by the American Society of Clinical Oncology was endorsed by the COG in December 2020.

The source guideline is published (Hesketh P, Kris MG, Basch E et al. JCO 2020; 38 (24): 2782-97.) and is available at: <https://ascopubs.org/doi/10.1200/JCO.20.01296>

The “Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline” developed by the Pediatric Oncology Group of Ontario was endorsed by the COG in February 2023.

The source guideline is published (Patel P, Robinson PD, Cohen M, et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. *Pediatr Blood Cancer*. 2022 Dec;69(12):e30001) and is available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.30001>

The purpose of these guidelines is to provide evidence-based recommendations for the prevention of acute chemotherapy-induced nausea and vomiting in children. The recommendations of the endorsed guidelines are presented below.

### Summary of Recommendations for the Prevention of Acute Chemotherapy-induced Nausea and Vomiting (CINV)

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>1. In pediatric patients receiving highly emetogenic chemotherapy (HEC), what strategies are recommended to prevent acute CINV?</b>	
a. Use a 5HT3RA + dexamethasone + (fos)aprepitant	Strong recommendation High quality evidence
b. Use palonosetron + dexamethasone in patients unable to receive (fos)aprepitant	Strong recommendation Moderate quality evidence
c. Use palonosetron + (fos)aprepitant in patients unable to receive dexamethasone	Strong recommendation Low quality evidence
d. Use palonosetron in patients unable to receive dexamethasone + (fos)aprepitant	Strong recommendation Moderate quality evidence
e. Consider adding olanzapine to other CPG-consistent antiemetics	Conditional recommendation Moderate quality evidence

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>2. In pediatric patients receiving moderately emetogenic chemotherapy (MEC), what strategies are recommended to prevent acute CINV?</b>	
a. Use a 5HT3RA + dexamethasone b. Use a 5HT3RA + (fos)aprepitant in patients unable to receive dexamethasone c. Use a 5HT3RA in patients unable to receive dexamethasone + (fos)aprepitant d. Consider using palonosetron as the preferred 5HT3RA in patients unable to receive dexamethasone + (fos)aprepitant e. Consider adding olanzapine to other CPG-consistent antiemetics in patients unable to receive dexamethasone + (fos)aprepitant	Strong recommendation Moderate quality evidence Strong recommendation Low quality evidence Strong recommendation Low quality evidence Conditional recommendation Low quality evidence Conditional recommendation Low quality evidence
<b>3. In pediatric patients receiving low emetogenic chemotherapy (LEC), what strategies are recommended to prevent acute CINV?</b>	
a. Use a 5HT3RA	Strong recommendation Low quality evidence
<b>4. In pediatric patients receiving minimally emetogenic chemotherapy (minEC), what strategies are recommended to prevent acute CINV?</b>	
a. Do not use prophylaxis routinely	Strong recommendation Very low quality evidence

CINV, chemotherapy-induced nausea and vomiting; 5HT3RA, serotonin-3 receptor antagonist; (fos)aprepitant, IV fosaprepitant or oral aprepitant

\*See Appendix 1

**III. Prevention and Treatment of Delayed Chemotherapy-Induced Nausea and Vomiting**

The “Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline” developed by the Pediatric Oncology Group of Ontario was endorsed by the COG in February 2023.

The source guideline is published (Patel P, Robinson PD, Cohen M, et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. *Pediatr Blood Cancer*. 2022 Dec;69(12):e30001) and is available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.30001>

The purpose of this guideline is to provide evidence-based guidance on strategies for delayed chemotherapy-induced nausea and vomiting prevention. The recommendations of the endorsed guideline are presented below.

## Summary of Recommendations for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting (CINV)

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>1. In pediatric patients receiving highly emetogenic chemotherapy (HEC), what strategies are recommended to prevent delayed CINV?</b>	
a. Use palonosetron in the acute phase as the preferred 5HT3RA in patients at high risk of delayed phase CINV	Strong recommendation Moderate quality evidence
b. Use oral aprepitant in the delayed phase, if (fos)aprepitant started in the acute phase	Strong recommendation High quality evidence
c. Add dexamethasone in the delayed phase in patients who received granisetron or ondansetron in the acute phase	Strong recommendation Moderate quality evidence
d. Consider adding dexamethasone in the delayed phase in patients who received palonosetron in the acute phase	Conditional recommendation Moderate quality evidence
e. Use dexamethasone in the delayed phase in patients unable to receive oral aprepitant	Strong recommendation Moderate quality evidence
f. Continue olanzapine in the delayed phase, if started in the acute phase	Strong recommendation Moderate quality evidence
g. Do not use 5HT3RAs in the delayed phase	Strong recommendation Low quality evidence
<b>2. In pediatric patients receiving moderately emetogenic chemotherapy (MEC), what strategies are recommended to prevent delayed CINV?</b>	
a. Consider using dexamethasone in the delayed phase	Conditional recommendation Low quality evidence
b. Continue oral aprepitant in the delayed phase in patients receiving single-day chemotherapy who received (fos)aprepitant in the acute phase	Strong recommendation Moderate quality evidence
c. Consider not using oral aprepitant in the delayed phase in patients receiving multi-day chemotherapy ( $\geq 3$ days) who received (fos)aprepitant in the acute phase	Conditional recommendation Low quality evidence
d. Continue olanzapine in the delayed phase, if started in the acute phase	Strong recommendation Low quality evidence
<b>3. In pediatric patients receiving low emetogenic chemotherapy (LEC), what strategies are recommended to prevent delayed CINV?</b>	
a. Do not use prophylaxis routinely in the delayed phase	Strong recommendation Very low quality evidence
<b>4. In pediatric patients receiving minimally emetogenic chemotherapy (minEC), what strategies are recommended to prevent delayed CINV?</b>	
a. Do not use prophylaxis routinely in the delayed phase	Strong recommendation Very low quality evidence

CINV, chemotherapy-induced nausea and vomiting; 5HT3RA, serotonin-3 receptor antagonist; (fos)aprepitant, IV fosaprepitant or oral aprepitant

\*See Appendix 1

#### IV. Prevention and Treatment of Anticipatory Chemotherapy-Induced Nausea and Vomiting

The “Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update”, developed by the Pediatric Oncology Group of Ontario, was endorsed by the COG in July 2021.

The source guideline is published (Patel P, Robinson PD, Devine KA, et al. *Pediatr Blood Cancer* 2021; e28947.) and is available at: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.28947>

The purpose of this guideline is to provide those caring for pediatric oncology or hematopoietic stem cell recipients up to 18 years of age with updated recommendations for the prevention of anticipatory CINV. The recommendations of the endorsed guideline are presented below.

#### Summary of Recommendations for the Prevention and Treatment of Anticipatory Chemotherapy-induced Nausea and Vomiting (CINV)

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>1. What strategies are recommended for primary prevention of anticipatory CINV in pediatric patients?</b>	
<p>1.1 Optimize acute and delayed CINV control to minimize the risk of anticipatory CINV</p> <p><i>Remarks:</i> This recommendation places high value on the consistent evidence that a history of acute or delayed CINV is a risk factor for anticipatory CINV. This recommendation also considers the other benefits of optimized acute or delayed CINV control including improved quality of life and the low risk of toxicities anticipated with CPG-consistent antiemetics.</p>	<p>Strong recommendation Moderate- quality evidence</p>
<b>2. What strategies are recommended for secondary prevention of anticipatory CINV in pediatric patients?</b>	
<p>2.1: Consider offering cooperative patients one or more of the following nonpharmacological interventions for secondary prevention of anticipatory CINV: hypnosis, systematic desensitization, or relaxation techniques.</p> <p><i>Remarks:</i> This recommendation places a high value on the minimal risks associated with these interventions. A conditional recommendation was made as the supporting evidence was limited to a small number of studies, the direct pediatric experience is scant and reports of the benefits of these interventions are inconsistent.</p>	<p>Conditional recommendation Low-quality evidence</p>

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<p>2.2 Consider using lorazepam for secondary prevention of anticipatory CINV.</p> <p><i>Remarks:</i> This recommendation remained unchanged from the 2014 CPG. It places a high value on the limited data demonstrating improved anticipatory CINV control in adults given benzodiazepines. It is a conditional recommendation because there is no direct pediatric evidence among included studies describing the use of benzodiazepines for this purpose.</p>	<p>Conditional recommendation Very low-quality evidence</p>
<p>2.3 We suggest that ginger not be used routinely for secondary prevention of anticipatory CINV.</p> <p><i>Remarks:</i> The panel made a conditional recommendation against the routine use of ginger given inconsistent study results in adult patients and the absence of pediatric data to support the use of ginger for this purpose. The panel also appreciated that the ginger formulations evaluated in included studies may not be comparable because doses of the components thought to be medically active are not uniformly reported.</p>	<p>Conditional recommendation Low-quality evidence</p>
<p>2.4 Do not use clonidine for secondary prevention of anticipatory CINV.</p> <p><i>Remarks:</i> The panel made a strong recommendation against the use of clonidine given its poor safety profile, lack of clear benefit, and lack of direct data for its use in pediatric patients for anticipatory CINV prevention.</p>	<p>Strong recommendation Low-quality evidence</p>
<p><b>3. What strategies are recommended for acute treatment of anticipatory CINV in pediatric patients?</b></p>	
<p>No recommendation can be made.</p> <p><i>Remarks:</i> No identified study directly evaluated an intervention aimed at the treatment of anticipatory CINV. The evidence describing primary and secondary anticipatory CINV prevention could not be extrapolated to make a recommendation.</p>	

\*See Appendix 1

**V. Treatment of Breakthrough and Prevention of Refractory Chemotherapy-induced Nausea and Vomiting**

The “Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update”, developed by the Pediatric Oncology Group of Ontario, was endorsed by the COG in December 2023.

The source guideline is published (Patel P, Robinson PD, Phillips R, et al. *Pediatr Blood Cancer* 2023; 70:e30395.) and is available at: <https://doi.org/10.1002/pbc.30395>

The purpose of this guideline is to provide those caring for pediatric oncology or hematopoietic stem cell recipients up to 18 years of age with updated recommendations for the treatment of breakthrough CINV and the prevention of refractory CINV. Breakthrough CINV is defined as nausea and/or vomiting that occurs during the acute or delayed phase of chemotherapy despite receipt of CINV prophylaxis. Refractory CINV occurs in patients who have experienced breakthrough CINV in previous chemotherapy blocks. The recommendations of the endorsed guideline are presented below.

**Summary of Recommendations for the Treatment of  
Breakthrough Chemotherapy-induced Nausea and Vomiting (CINV) and  
Prevention of Refractory CINV**

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>1. What strategies are recommended to treat breakthrough CINV in pediatric patients?</b>	
1.1 Escalate the antiemetic agents provided in the current chemotherapy block to those recommended for CINV prophylaxis for chemotherapy of the next higher level of emetogenic risk in pediatric patients with breakthrough CINV receiving acute and delayed CINV prophylaxis recommended for minEC, LEC or MEC.	Strong recommendation Low-quality evidence
1.2 In pediatric patients receiving acute or delayed CINV prophylaxis recommended for HEC who are not already receiving palonosetron, consider giving palonosetron instead of ondansetron/granisetron at the next scheduled ondansetron/granisetron administration time during the acute phase of the current chemotherapy block	Conditional recommendation Low-quality evidence
1.3 In pediatric patients receiving acute or delayed CINV prophylaxis recommended for HEC, consider adding one or more of the following antiemetic agents in the current chemotherapy block in patients who are not already receiving them: <ul style="list-style-type: none"> <li>• dexamethasone</li> <li>• (fos)aprepitant<sup>†</sup></li> <li>• olanzapine</li> </ul>	Conditional recommendation Moderate-quality evidence
1.4 In pediatric patients receiving acute or delayed CINV prophylaxis recommended for HEC, consider adding metoclopramide in the current chemotherapy block in pediatric patients unable to receive olanzapine	Conditional recommendation Low-quality evidence

RECOMMENDATIONS	Strength of Recommendation and Quality of Evidence*
<b>2. What strategies are recommended to prevent refractory CINV in pediatric patients who have experienced breakthrough CINV?</b>	
2.1 Use CPG-consistent antiemetic agents that controlled breakthrough CINV in previous chemotherapy blocks	Strong recommendation Low-quality evidence
2.2 Use the antiemetic agents recommended for CINV prophylaxis for chemotherapy of the next higher level of emetogenic risk in patients who did not experience control of breakthrough CINV in previous chemotherapy blocks and are receiving minEC or LEC	Strong recommendation Moderate-quality evidence
2.3 Consider adding one or more of the following, if not already receiving them, in patients who did not experience control of breakthrough CINV in previous chemotherapy blocks and are receiving MEC or HEC: <ul style="list-style-type: none"> <li>• dexamethasone</li> <li>• (fos)aprepitant<sup>†</sup></li> <li>• olanzapine</li> </ul>	Conditional recommendation Moderate-quality evidence
2.4 Consider offering one or more of the following to patients who experience refractory CINV despite receipt of all suitable CPG-consistent antiemetic agents: <ul style="list-style-type: none"> <li>• CINV-focused dietary counselling</li> <li>• yoga</li> </ul>	Conditional recommendation Low-quality evidence

HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; LEC, low emetogenic chemotherapy; minEC, minimally emetogenic chemotherapy.

<sup>†</sup>IV fosaprepitant or oral aprepitant

## Appendix 1: GRADE

### Strength of Recommendations:

<b>Strong Recommendation</b>	When using GRADE, panels make strong recommendations when they are confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects.
<b>Weak/Conditional Recommendation</b>	Weak recommendations indicate that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but the panel is less confident.

### Strength of Recommendations Determinants:

Factor	Comment
Balance between desirable and undesirable effects	The larger the difference between the desirable and undesirable effects, the higher the likelihood that a strong recommendation is warranted. The narrower the gradient, the higher the likelihood that a weak recommendation is warranted
Quality of evidence	The higher the quality of evidence, the higher the likelihood that a strong recommendation is warranted
Values and preferences	The more values and preferences vary, or the greater the uncertainty in values and preferences, the higher the likelihood that a weak recommendation is warranted
Costs (resource allocation)	The higher the costs of an intervention—that is, the greater the resources consumed—the lower the likelihood that a strong recommendation is warranted

### Quality of Evidence

<b>High Quality</b>	Further research is very unlikely to change our confidence in the estimate of effect
<b>Moderate Quality</b>	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
<b>Low Quality</b>	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
<b>Very Low Quality</b>	Any estimate of effect is very uncertain

Guyatt, G.H., et al., *GRADE: an emerging consensus on rating quality of evidence and strength of recommendations*. BMJ, 2008; 336: 924-926.

Guyatt, G.H., et al., *GRADE: going from evidence to recommendations*. BMJ, 2008; 336: 1049-1051.